Company Description
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.
In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies.
Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020.
The company was incorporated in 2018 and is based in Somerville, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 27, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 312 |
| CEO | Michael Nally |
Contact Details
Address: 101 South Street, Suite 900 Somerville, Massachusetts 02143 United States | |
| Phone | (888) 469-0055 |
| Website | generatebiomedicines.com |
Stock Details
| Ticker Symbol | GENB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 2100782 |
| CUSIP Number | 370920100 |
| ISIN Number | US3709201004 |
| Employer ID | 83-1630228 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Nally, M.B.A. | Chief Executive Officer and Director |
| Gevorg Grigoryan, Ph.D. | Co-Founder and Chief Technology Officer |
| Beth Grous | Chief People Officer |
| Aarif Khakoo, M.D., M.B.A. | Chief Scientific Officer |
| Laurie Lee, M.D. | Chief Medical Officer |
| Sean Martin, J.D. | Chief Legal Officer and General Counsel |
| Jason Silvers, M.D., J.D. | President and Chief Financial Officer |
| Noubar B. Afeyan, Ph.D. | Chairperson of the Board |
| Frances Arnold, Ph.D. | Director |
| Stéphane Bancel, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 8-K | Current Report |
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | 424B4 | Prospectus |
| Feb 26, 2026 | EFFECT | Notice of Effectiveness |
| Feb 26, 2026 | CERT | Certification by an exchange approving securities for listing |
| Feb 24, 2026 | 8-A12B | Registration of securities |
| Feb 23, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 13, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 4, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 23, 2025 | DRS | [Cover] Draft Registration Statement |